Abstral® ,Manufactured and packaged by Recipharm AB for Kyowa Hakko Kirin, has been approved in Japan

Abstral® ,Manufactured and packaged by Recipharm AB for Kyowa Hakko Kirin, has been approved in Japan

Approval to manufacture highly potent compound for breakthrough pain relief in cancer treatment granted

23 September 2013, Recipharm Stockholm  is pleased to announce that the company was informed on September 20, 2013 by the R&D-based pharmaceutical company, Kyowa Hakko Kirin Co. Ltd. (Tokyo, Japan, President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") that Abstral® sublingual tablet (nonproprietary name: fentanyl citrate; referred to below as "Abstral®"), has been approved for manufacturing and marketing by Japan's Ministry of Health, Labour and Welfare(MHLW). The approval allows Recipharm to carry out commercial scale manufacturing and packaging of Abstral®   for supply to the Japanese market through Kyowa Hakko Kirin.

The drug product, Abstral® is a novel, highly potent, rapid disintegration, sublingual (under the tongue) formulation of fentanyl citrate. This well-established opioid is used extensively for fast relief and management of episodes of breakthrough pain experienced by cancer patients that are already in receipt of opioid analgesics for cancer pain. 

Japanese regulatory agency assessed Recipharm's suitability through detailed analysis of the company's history, capabilities, proven track record and the reliability of the supply chain set to take the product through to Japan, together with a thorough review of all clinical data and product documentation.

Recipharm will compress and formulate Abstral®   in tablet dosage at its manufacturing site in Årsta, with all packaging performed at the company's Jordbro complex. Quality control will be initiated in laboratories located in central Stockholm.           

Thomas Beck, Director of Quality and Qualified Person at Recipharm Stockholm commented: "We are delighted to receive Japan's MHLW approval to carry out a combination of both the manufacturing and the packaging of such a product, for onward  supply to the Japanese market. Indeed, we are pleased, both because securing such authorisation from a regulatory body outside of the EU is an extremely complicated process, especially in the case of Japan, and due to the fact that Abstral® is a highly innovative drug that enables fast relief of pain endured by patients undergoing cancer treatment."

For media enquiries, please contact De Facto Communications on: +44 (0) 207 203 6740 or e-mail:[email protected].     


Notes to editors

About Recipharm
Recipharm AB is a leading contract development and manufacturing organization (CDMO) based in Sweden employing some 1600 employees. The Company operates development and manufacturing facilities in Sweden, France, the UK, Germany and Spain and is headquartered near Stockholm. Recipharm supplies the global pharmaceuticals market with hundreds of different products in multiple dosage forms that include solid dose, semi solids, steriles (liquids and freeze dried), beta-lactams, hormones and dry powder inhalers, oral liquids and granulates. For more information visit www.recipharm.com.

About Kyowa Hakko Kirin                                                                

Kyowa Hakko Kirin is a leading biopharmaceutical company in Japan focusing on its core business area of oncology, nephrology and immunology/allergy. Kyowa Hakko Kirin leverages antibody-related leading-edge technologies to discover and develop innovative new drugs aiming to become a global specialty pharmaceutical company which contributes to the health and well-being of people around the world.  For more information, visit http://www.kyowa-kirin.com.

For media enquiries, please contact Tristan Jervis on +44 (0) 207 203 6740 or e-mail:[email protected]




Tristan Jervis

Managing Partner


Description: Description: Description: DF logo

Holborn Gate, 26 Southampton Buildings

London WC2A 1BP


Telephone: +44 (0)207 203 6742

Direct: +44 (0)207 203 6740

E-mail: [email protected]